The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | CAR T-cells for myeloma: an update
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, gives us an update on CAR T-cells for myeloma. Dr Raje discusses the results seen with idecabtagene vicleucel (bb2121), incuding toxicity, bone marrow MRD negativity and progression-free survival, and highlights the refractory nature of the patients that received this therapy. She also covers the key remaining questions for investigation.
